Immunotherapy includes strategies to enhance immune cell activation in patients to better target cancer.

 

​Cellmover has developed a library of peptides and nanobodies directed at specific proteins in T cells and NK cells. By targeting these proteins, the peptides and nanobodies mediate increased survival and persistence of immune cells within the tumor microenvironment.